Zongertinib

Boehringer Ingelheim has initiated the JADE Phase II clinical study to evaluate BI 1584862, a potential first-in-class oral treatment for geographic atrophy, a severe form of age-related macular degeneration.

The American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago will focus on "Unifying Cancer Science and Medicine" with presentations spanning from basic research to practice-changing clinical trials.

Boehringer Ingelheim has secured global commercialization rights for treatments co-developed with Tessellate Bio targeting tumors dependent on alternative lengthening of telomeres (ALT), present in 10-15% of all cancers.

Boehringer Ingelheim reached 66 million patients in 2024, an 8% increase from the previous year, while investing €6.2 billion (23.2% of net sales) in research and development.

Daiichi Sankyo has entered a $300 million partnership with Alteogen to develop a subcutaneous formulation of the cancer drug Enhertu, potentially making it the first injectable ADC.